Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies

J. Arikawa, J.-S. Yao, K. Yoshimatsu, I. Takashima, and N. Hashimoto

1 Institute of Immunological Science and 2 Department of Veterinary Public Health, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan

Accepted December 27, 1991

Summary. To investigate the role of Hantaan virus envelope glycoprotein in infection, a panel of monoclonal antibodies (MAbs) was examined in vitro with several serological tests and in vivo by passive transfer experiments in mice. An antigenic site, specific for the inhibition of infected cell focus was detected with the focus inhibition neutralization test (FINT), in addition to the neutralization related antigenic sites, which were revealed by the ordinary focus reduction neutralization test (FRNT). Suckling mice were given the MAbs by passive transfer followed by lethal Hantaan virus challenge. All neutralizing MAbs detected by either FRNT or FINT protected all mice from lethal infection, confirming the importance of the antigenic sites as a protective antigen. Mice given non-neutralizing MAbs by passive transfer, however, began to die earlier than the control group; mean time to death (18.2 ± 2.1 to 21.5 ± 2.8 days) being significantly shorter than that of the control group (25.8 ± 1.8, p < 0.01, Mann-Whitney, U probability test). Virus titers in brains of mice which died early, were about 10 times higher than those of control mice. These results indicated the early death phenomenon of mice which was mediated by the anti-virus antibody.

Introduction

Haemorrhagic fever with renal syndrome (HFRS) is a rodent borne viral disease characterized by fever, renal disorder and hemorrhagic manifestations [34, 35]. HFRS patients have been reported throughout Eurasia and parts of Africa [12] particularly in China [8, 27], Korea [11], Northern [10], and Eastern Europe [15].

Hantaan virus is the causative agent of HFRS and classified in the family Bunyaviridae, genus Hantavirus [24]. This virus has two different glycoprotein projections (G1 and G2) on the surface of the virion [25]. In our previous
experiments, nine distinct antigenic sites, two on G1 and seven on G2, were demonstrated by competitive binding assay using a panel of monoclonal antibodies (MAb) to the G1 and G2 proteins. In addition, some of the MAbs to both the G1 and G2 proteins had neutralizing activity [1]. Therefore, similar to other enveloped viruses, the G1 and G2 proteins of the Hantaan virus have been considered to play an important role in virus infection.

Recently, it was found that the MAbs to the antigenic sites having hemagglutinating activity on G2 protein mediated the enhancement of hantavirus infection of macrophages in vitro [36]. This may be caused by the enhanced attachment of virus-MAb complex to the Fc receptor on the macrophage. Although the infected macrophage is thought to be responsible for the spread of infection in rodents and humans, the actual role of the antigenic sites on the viral envelope protein in the infection remains unclear.

To investigate the immunological role of antigenic sites in Hantaan virus infection in more detail, a panel of monoclonal antibodies (MAbs) was examined in vitro by two different neutralization tests, FRNT and FINT; and in vivo by passive transfer experiments in suckling mice.

Materials and methods

Cell culture and virus

The E6 clone of Vero cells (ATCC C1008, CRL 1586) [25] was grown in Eagle's minimum essential medium (Eagle's MEM, Nissui Co., Tokyo Japan) supplemented with 5% fetal calf serum and 0.292 g/l of L-glutamine. Hantaan virus, strain 76-118, isolated from the Korean field rodent Apodemus agrarius coreae [13], was used throughout this study. Virus was inoculated into the Vero E6 cell monolayer and maintained with the same medium described above. Four days after infection, culture fluid was collected and stored at −80 °C as stock virus. The infectivity titer of the virus was measured using the peroxidase-anti-peroxidase (PAP) method as described previously [30].

Indirect immunofluorescent antibody (IFA) test

Vero E6 cells infected with Hantaan virus, strain 76-118 were monodispersed in culture medium and dropped onto spot slide glasses. They were incubated at 37 °C in a CO2 incubator for four hours to extend the cells on the glass, then washed with PBS. The cells were fixed with cold acetone and used as antigen. Fluorescent isothiocyanate (FITC) conjugated anti-mouse immunoglobulins or anti mouse IgM (μ chain specific) (goat; Cappel Laboratories, Cochranvilla, Pa.) were used as the second antibody. IFA titers were expressed as the reciprocals of the highest dilution giving specific immunofluorescence in the infected cell cytoplasm. IFA titers of 1 : 10 or more were regarded as positive [3].

Focus reduction neutralization test (FRNT) and focus inhibition neutralization test (FINT)

FRNT was described previously [20]. Briefly, a serial 10-fold dilution of mouse ascitic fluid or immune serum was mixed with an equal volume of virus suspension. The mixture was kept at 37 °C for 1 hr, then inoculated onto Vero E6 cell monolayers in 96 well plates. After incubation for 1 hr, the inoculum was removed and the monolayers were covered with overlay medium (MEM containing 1.5% carboxymethylcellulose and 5% FCS). After
incubation for 7 days at 37 °C in a CO₂ incubator, the cell monolayer was washed with phosphate buffered saline (PBS) and fixed with methanol for 10 min at room temperature. Infected cell foci were stained by the peroxidase-anti-peroxidase (PAP) method with rabbit immune sera and the number of infected cell foci was counted. FRNT titer was regarded as the highest dilution of ascitic fluid causing 80% or more reduction in the number of infected foci formed in the presence of control ascitic fluid instead of antibody. In the focus inhibition neutralization test (FINT), a virus suspension containing 30 to 50 focus-forming units (FFU) of virus per 50 μl was inoculated onto Vero cell monolayers in 96 well plates. After incubation for 1 hr, the inoculum was removed and the cells were covered with overlay medium containing serial 10-fold dilutions of ascitic fluid. The FINT titer was defined by the 80% reduction method as described for the FRNT titer.

Membrane FA

Membrane FA was performed according to the method of Franko et al. [4]. Briefly, a Vero E6 cell monolayer infected with Hantaan virus, strain 76–118 was monodispersed by PBS containing 0.1% trypsin and 0.02% EDTA. The cells were washed twice with PBS by low speed centrifugation. The cell pellet was resuspended with a 1 : 100 dilution of ascitic fluid or control ascitic fluid, then incubated for 1 hr at 37 °C. After 3 PBS washes, the cells were mixed with FITC labeled anti-mouse Ig(G,M,A) (goat; Cappel Laboratories, Cochranville, Pa.). After incubation for 1 hr at 37 °C, the cells were washed as above and finally mixed with 50% (v/v) glycerin in PBS. Cells were examined under the fluorescence microscope.

Passive protection studies with MAbs to Hantaan virus

Outbred ICR mice were obtained from Shizuoka Laboratories (Shizuoka, Japan) and mated to produce suckling mice. A group of 8 to 10 suckling mice (less than 24 hr after birth) were inoculated subcutaneously (s.c.) with 50 μl of undiluted ascitic fluid containing a MAb specific for Hantaan virus, strain 76–118 (Table 1) or normal ascitic fluid. Four hours after the adoptive transfer of the ascitic fluid, mice were challenged with a s.c. injection of 5 × 10³ FFU (10 LD₅₀) of Hantaan virus, strain 76–118. Survival rates were recorded for 5 weeks after the challenge. Serum specimens of surviving mice were obtained by cardiac puncture under ether anesthesia. The filter paper method [3] was used for collecting blood from dead or moribund mice. The passive protection study was carried out one time to each MAb clones, except to clone 6D4. All animals were treated according to the Laboratory Animal Control Guidelines in our institute which was basically in conformity to National Institutes of Health-American Association of Laboratory Animal Control Guidelines. All the animal experiments were carried out in a class P3 facility.

Titration of virus in brain, lung, and spleen

Organs were removed from mice when they were moribund, dead, or 35 days post challenge (surviving mice). Each organ was homogenized as a 10% suspension in Eagle’s MEM containing 5% fetal calf serum, 60 μg/ml of kanamycin, 400 units/ml of penicillin, and 400 μg/ml of streptomycin. Ten-fold dilutions of the suspension were inoculated onto Vero E6 cell monolayers in 96 well plates. After incubation for 1 hr at 37 °C, the inoculum was removed and replaced with overlay medium. After incubation for 7 days, infectivity titers were measured by the PAP method as described previously [30].

Results

Characterizations of antigenic sites using monoclonal antibodies

Table 1 shows the list of MAbs used in this study. Names of MAb clones, antigenic sites recognized by the clones and HAI activities have been described
Table 1. Characterization of polyclonal and monoclonal antibodies by an in vitro assay

| Antigenic site | MAb   | HAI activity | Neutralization bya | Membrane FA |
|---------------|-------|-------------|-------------------|-------------|
|               |       |             | focus reduction (FRNT) | focus inhibition (FINT) |             |
| G1-a-(1)      | 8B6   | -           | -                 | +           |
| G1-a-(2)      | 6D4   | -           | -                 | +           |
|               | 10F11 | -           | -                 | +           |
| G1-b          | 2D5   | + + +       | +                 | + + +       |
|               | 3D5   | + + +       | + +               | + + +       |
|               | 16D2  | + + +       | + +               | + + +       |
| G2-a-(1)      | HCO2  | +           | +                 | + + +       |
| G2-a-(2)      | 16E6  | +           | +                 | + + +       |
| G2-b          | EBO6  | + + +       | -                 | +           |
| G2-c          | 11E10 | + + +       | +                 | + + +       |
| G2-d          | 17G6  | + +         | -                 | +           |
|               | 3D7   | + + +       | -                 | +           |
|               | 5B7   | + + +       | -                 | +           |
| G2-e          | 20D3  | + + +       | -                 | +           |
| G2-f-(1)      | 8E10  | + + +       | -                 | + + +       |
|               | 1C6   | + + +       | -                 | + + +       |
|               | 1G8   | + + + +     | -                 | + + +       |
|               | 23G10-2 | + + + | - | + + + | + + + |
|               | 3B6   | + + +       | -                 | +           |
| G2-f-(2)      | 23G10-1 | + +     | - | - | + |
|               | 7G6   | + +         | -                 | +           |
|               | 18F5  | +           | -                 | +           |
| G2-f-(3)      | GDO5  | -           | -                 | +           |
| Anti Hantaan mouse immunesera | + + | + + + | + + | + |

a – Less than 80% focus reduction or inhibition at 1:10 dilution; more than 80% focus reduction or inhibition at 1:10 (+), 1:100 (++) 1:1,000 (+++) dilution

in our previous report [1]. The immunoglobulin isotypes of clones HCO2 and 18F5 were IgG2b and IgG2a, respectively. The rest of the clones possessed IgG1 isotype. Neutralizing activities of the MAbs to Hantaan virus, strain 76-118 were examined using two different neutralization tests; FRNT and FINT. As shown in Table 1, antigenic sites G1-b, G2-a and G2-c related to virus neutralization in vitro and these results were the same as those obtained by plaque reduction neutralization test in our previous report [1]. All the MAb clones positive in FRNT also inhibited focus formation (FINT). Clones 8E10
Antigenic sites on the envelope protein of Hantaan virus and 1C6 to antigenic site G2-f however, were negative by FRNT, but inhibited focus formation. Thus, additional neutralizing antigenic sites were found out by FINT.

Expression of viral antigens on the surface of infected cells was examined by the membrane FA test. As listed in Table 1, all the MAb clones reacted with unfixed infected cells. The intensity of FA was similar regardless of the MAb clones used.

**Passive protection of suckling mice with MAbs**

To examine the antigenic sites related to protective immunity in suckling mice, at least one MAb clone representative of each of the different antigenic sites was selected and passively transferred to suckling mice followed by a lethal challenge with a high dose of virus. The results are summarized in Table 2.

**Table 2. Passive protection of suckling mice with monoclonal antibodies to Hantaan virus, strain 76-118**

| Antigenic site | MAb  | No. mice | Mean time to death<sup>b</sup> (Day± SD) |
|---------------|------|----------|-------------------------------------|
|               |      | Tested   | Died      | Sero-positive IgG<sup>c</sup> (GMT)<sup>a</sup> | IgM (GMT) |                           |
| G1-a-(1)      | 8B6  | 10       | 10        | 10 (970) | 0  (< 10) | 18.2 ± 2.1<sup>c</sup>     |
| G1-a-(2)      | 6D4  | 10       | 0         | 10 (1,016) | 0  (< 10) | survived                    |
|               | 6D4  | 10       | 0         | 10 (676)  | 0  (< 10) | survived                    |
| G1-b          | 16D2 | 10       | 0         | 0 (< 10)  | 0  (< 10) | survived                    |
| G2-a-(1)      | HCO2 | 10       | 0         | 0 (< 10)  | 0  (< 10) | survived                    |
| G2-a-(2)      | 16E6 | 10       | 0         | 10 (520)  | 0  (< 10) | survived                    |
| G2-b          | EBO6 | 10       | 5         | 10 (4,064) | 0  (< 10) | 20.6 ± 3.2<sup>c</sup>      |
| G2-c          | 11E10| 10       | 0         | 5 (226)   | 1 (160) | survived                    |
| G2-d          | 17G6 | 10       | 4         | 10 (4,188) | 1 (40) | 20.3 ± 5.6<sup>c</sup>      |
| G2-e          | 20D3 | 10       | 10        | 10 (2,048) | 0  (< 100) | 20.0 ± 1.6<sup>c</sup>     |
| G2-f-(1)      | 8E10 | 10       | 0         | 10 (279)  | 0  (< 10) | survived                    |
| G2-f-(2)      | 23G10-1 | 10 | 8        | 10 (761) | 1 (160) | 21.5 ± 2.8<sup>c</sup>      |
| G2-f-(3)      | GD05 | 8        | 7         | 8 (1,076) | 1 (40) | 18.9 ± 3.2<sup>c</sup>      |
| Anti Hantaan mouse immunoserum | | 10 | 0 | 3 (2,037) | 2 (40) | survived                    |
| Normal ascitic fluid | | 10 | 9 | 10 (549) | 0  (< 10) | 25.8 ± 1.8                |

<sup>a</sup> Geometric mean IFA titer  
<sup>b</sup> Mean time to death was calculated among the mice that died within observation period (35 days)  
<sup>c</sup> p < 0.01
Table 3. Hantaan virus titers in tissues of challenged mice that passively received polyclonal or monoclonal antibodies

| Anti-genic site | MAb       | Mean virus titers (log10) in brain | lung | spleen |
|----------------|-----------|-----------------------------------|------|--------|
|                |           |                                   |      |        |
| G1-a-(1)       | 8B6       | 5.94                              | 4.87 | 4.38   |
| G1-a-(2)       | 6D4       | -                                 | -    | -      |
| G1-b           | 16D2      | -                                 | -    | -      |
| G2-a-(1)       | HCO2      | -                                 | -    | -      |
| G2-a-(2)       | 16E6      | -                                 | -    | -      |
| G2-b           | EBO6      | 5.94                              | 5.26 | -      |
| G2-c           | 11E10     | -                                 | -    | -      |
| G2-d           | 17G6      | 6.15                              | 5.12 | -      |
| G2-e           | 20D3      | 5.88                              | 5.86 | -      |
| G2-f-(1)       | 8E10      | -                                 | -    | -      |
| G2-f-(2)       | 23G10-1   | 6.08                              | 4.64 | -      |
| G2-f-(3)       | GDO5      | 6.18                              | 5.49 | 3.52   |
| Anti Hantaan mouse immunesera |       | -                                 | -    | -      |
| Medium         |           | 5.08                              | 4.90 | -      |

* a log10 FFU/g tissue  
* b Less than 200 FFU/g tissue

challenge with Hantaan virus, strain 76–118 (Table 2). All the FRNT MAbs (clones 16D2, HCO2, 16E6 and 11E10) completely prevented lethal infection. In addition, clones 16D2, HCO2 and 11E10 protected all or half of the mice from infection since they had no sero-conversion after the challenge. Clone 8E10, positive in FINT but negative in FRNT, protected all the mice from lethality but failed to protect from infection. Thus, either G1 or G2 envelope proteins were responsible for induction of protective immunity. Interestingly, clone 6D4 to antigenic site G1-a-2, which had no neutralizing activity in either FRNT or FINT, protected all the mice from lethal infection. The experiment was repeated and the same result was obtained. The rest of the non-neutralizing clones were divided into two groups depending on the protective activity from lethal infection. Most of the mice which received MAb clones 8B6, 20D3, 23G10-1 and GDO5 died, but clones EBO6 and 17G6 partially protected the mice from lethal infection.

*Early death of the mice passively transferred with MAb*

As described above, non-neutralizing MAbs failed to protect the mice from lethal infection. Mean time to death for mice are listed in the right hand column.
Antigenic sites on the envelope protein of Hantaan virus 277

of Table 2. Although the survival rates differed between clones transferred, the mean time to death among groups of mice ranged from 18.2 ± 2.1 (clone 8B6) to 21.5 ± 2.8 days (clone 23G10-1) and were significantly shorter than those of the control group (25.8 ± 1.8, p < 0.01, Mann-Whitney U probability test). Survival curves for the mice transferred with the non-protective antibodies (clones GDO5, 8B6 and 20D3) are shown in Fig. 1a. In all groups, mice began to die 4 to 5 days earlier than control mice. On the other hand, though clone 17G6 or EBO6 partially protected the mice from lethal infection, they began to die earlier than the controls (Fig. 1b).

_Virus titers in tissues of challenged mice that received passively transferred polyclonal and monoclonal antibodies_

Virus titers in brain, lung and spleen tissues of immunized mice were measured and compared with those of the control group. Organs were collected when mice were moribund, dead, or 35 days after the challenge (surviving mice). Virus was recovered from the organs from dead mice, but not from those of the survivors. Higher virus titers for dead mice were detected in brain tissues

Fig. 1. Passive protection study of suckling mice. Outbred ICR suckling mice (less than 24 hr old) were inoculated s.c. with 50 μl of normal ascitic fluid or MAbs to Hantaan virus envelope protein. Four hours after the transfer, mice were challenged by s.c. infection with 5 × 10^3 FFU (10 LD50) of Hantaan virus, strain 76–118. a Transferred with normal ascitic fluid (□) or MAb clones GDO5 (○), 8B6 (■), 20D3 (●). b Transferred with normal ascitic fluid (□) or MAb clones 17G6 (●) and EBO6 (○)
rather than in the lung or spleen. Virus titers obtained from brain tissues were about ten times higher than those from control mouse brain, although the virus titers in lung tissues were similar for control and immunized mice.

**Discussion**

One of the G1 antigenic sites and two of the G2 sites of Hantaan virus envelope protein are involved in virus neutralization, as demonstrated by plaque reduction neutralization with a panel of MAbs [1]. In the present study, an additional antigenic site related to virus neutralization was identified with MAb clones 8E10 and 1C6, which were positive in FINT but negative in FRNT (Table 1). In paramyxoviruses, when the MAb to fusion (F) protein was contained in the agar overlay medium, plaque formation was effectively inhibited comparing to its plaque reduction neutralization activity [31]. The inhibition of plaque formation is considered to be caused by the inhibition of cell to cell spread of virus infection, since the (fusion) F protein mediated the cell to cell fusion but not relate to the virus attachment to cell. We have reported that Hantaan virus has cell fusion activity under the low pH condition [2]. Therefore, to examine the neutralization mechanism related to the newly recognized antigenic site, attachment blocking activity as well as fusion inhibition activity of clones 8E10 and 1C6 will be required.

To investigate the role of Hantaan virus envelope protein in infection in vivo, suckling mice were passively given MAbs followed by Hantaan virus challenge. All the animals transferred with FRNT MAbs either to G1 or G2 protein were completely protected from Hantaan virus challenge because all the mice survived and most of them showed no sero-conversion (Table 2). These results were consistent with a recent report by Schmaljohn et al. [23], in which hamsters were passively protected from infection only with MAbs having plaque reduction neutralizing activity. In addition, MAb clone 8E10, which recognized the antigenic site related to neutralization discovered here, also protected suckling mice against lethal infection, although it did not protect the mice from infection (Table 2). The MAb may retard the spread of viral infection in mice. The fatal outcome of experimentally inoculated mice or rats was strictly dependent on the age of the animals. Complete resistance from lethal Hantaan virus challenge was gained at two weeks of age in mice [9, 18] and at one week in the rat [37]. Therefore, the delay in viral spread at an early stage of infection may result in survival at a later stage due to age-dependent resistance. These results confirmed the important role of envelope protein as protective antigen.

Clone 6D4 to antigenic site G1-a-2 protected all the mice from lethal infection, although the antibody had no neutralizing activity in either FRNT or FINT and also had no HAI activity. The protective effect of non-neutralizing antibody in passively transferred mice has been reported in various viruses [7, 14, 20–22, 26, 29]. All the reports ascribed the protective mechanisms to cell mediated immune responses against infected cells, such as complement-mediated lysis of infected cells, or antibody dependent cell-mediated cytotoxicity (ADCC).
Since this MAb clone was positive in the membrane FA test but lacked complement binding activity (subclass IgG1), ADCC rather than complement-mediated cytolysis of infected cells was suggested. No protective activity was detected in the remaining non-neutralizing clones for reasons which remain to be determined. To examine relationship between this phenomenon and antigenic site (G1-a-2) in more detail, we are now planning to carry out similar experiments with the other MAb clone 10F11, which binds to the same antigenic site as clone 6D4.

As shown in Fig. 1 and Table 2, mice began to die earlier than the control group and the mean time to death were significantly shorter than those of control mice. Virus titers in the brains of mice that died early \((7.5 \times 10^5\) to \(1.5 \times 10^6\) FFU/g), were apparently higher than those of control mice \((1.2 \times 10^5\) FFU/g), although the virus titers in the lungs were similar. Several animal experiments have indicated that the death of challenged mice is closely related to virus titers in brain tissues and virus titers of a lethal threshold are around \(10^5\) FFU per gram \([17, 18, 28]\). Recently, the antibody dependent enhancement (ADE) of hantavirus infection to Fc-receptor bearing cells such as macrophages, caused by enhanced binding of virus and antibody complex via Fc receptors on the cell has been reported \([36]\). Since macrophages are susceptible to hantavirus infection and are believed to be responsible for the spread of infection in mice \([16]\), ADE of infection to macrophages is considered a plausible mechanism for the rapid growth of virus in the brain. To examine if the early death presented here is related to high virus titers in the brain, studies on the kinetics of virus growth in various organs of mice with or without antibody transfer are now in progress. Similar phenomena have been reported in mice challenged with yellow fever and JE \([5]\), Langat \([32]\) and rabies viruses \([19]\), as well as cat coronavirus \([33]\), but few reports have discussed the mechanisms involved. Gould et al. \([6]\) reported that enhanced neurovirulence in mice infected with yellow fever virus is not mediated through Fc and complement receptor-bearing macrophages, but that the cytotoxicity to infected brain tissues is caused by antibodies. There were found to be severe pathologic changes in the brain tissue of antibody transferred mice compared with controls, however virus titers in the brain were similar regardless of pre-existing antibody. In the present study, however, the high virus titers in brain tissues without histological changes suggest a different mechanism from that shown in yellow fever virus infection.

Acknowledgements
This study was supported in part by Grants-in-Aid for Scientific Research (No. 02806056) and for Development Scientific Research (No. 03558009) from the Ministry of Education, Science and Culture of Japan.

References
1. Arikawa J, Schmaljohn AL, Dalrymple JM, Schmaljohn CS (1989) Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies. J Gen Virol 70: 615–624
2. Arikawa J, Takashima I, Hashimoto N (1985) Cell fusion by haemorrhagic fever with renal syndrome (HFRS) viruses and its application for titration of virus infectivity and neutralization antibody. Arch Virol 86: 303–313

3. Arikawa J, Takashima I, Hashimoto N, Takahashi K, Yagi K, Hattori K (1986) Epidemiological studies of hemorrhagic fever with renal syndrome (HFRS) related virus infection among urban rats in Hokkaido, Japan. Arch Virol 88: 231–240

4. Fanko MC, Gibbs CJ Jr, Lee PW, Gajdusek DC (1983) Monoclonal antibodies specific for hantaan virus. Proc Natl Acad Sci USA 80: 4149–4153

5. Gould EA, Buckley A (1989) Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J Gen Virol 70: 1605–1608

6. Gould EA, Buckley A, Groeger BK, Cane PA, Doenhoff M (1987) Immune enhancement of yellow fever virus neurovirulence for mice: studies of mechanisms involved. J Gen Virol 68: 3105–3112

7. Grosfeld H, Velan B, Leitner M, Cohen S, Lustig S, Lachmi BE, Shafferman A (1989) Semliki forest virus E2 envelope epitopes induce a non-neutralizing humoral response which protects mice against lethal challenge. J Virol 63: 3416–3422

8. Jiang YT (1983) A preliminary report on hemorrhagic fever with renal syndrome in China. Chinese Med J 96: 265–268

9. Kim GR, McKee Jr KT (1985) Pathogenesis of hantaan virus infection in suckling mice: clinical, virologic and serologic observations. Am J Trop Med Hyg 34: 388–395

10. Lähdevirta J, Savola J, Brunmer-Korvenkontio M, Berndt R, Illikainen R, Vaheri A (1984) Clinical and serological diagnosis of Nephropathia epidemic, the mild type of hemorrhagic fever with renal syndrome. J Infect Dis 9: 230–238

11. Lee HW, Lee PW, Baek LJ, Chu YK (1989) Seroepidemiological features of haemorrhagic fever with renal syndrome in the Republic of Korea from 1980 to 1987. JE HFRS Bull 3: 45–48

12. Lee HW, Lee PW, Baek LJ, Chu YK (1990) Geographical distribution of hemorrhagic fever with renal syndrome and hantaviruses. Arch Virol [Suppl] 1: 5–18

13. Lee HW, Lee PW, Johnson KM (1978) Isolation of the etiological agent, Korean hemorrhagic fever. J Infect Dis 137: 298–308

14. McLain L, Dimmock NJ (1989) Protection of mice from lethal influenza by adoptive transfer of non-neutralizing haemagglutination-inhibiting IgG obtained from the lungs of infected animals treated with ineffective interfering virus. J Gen Virol 70: 2615–2624

15. Myasnikov YuA, Rezapkin GV, Shuikova ZV, Tkachenko EA, Ivanova AA, Nurgaleeva RG, Stepankenko AG, Vereschagin NN, Loginov AI, Bagan RN, Zaitseva AA, Levacheva ZA, Bobylkova TV, Ishcheryakova AM, Boruta VV (1984) Antibodies to the HFRS virus in the human population of European RSFSR as detected by radioimmunoassay. Arch Virol 79: 109–115

16. Nagai T, Tanishita O, Takahashi Y, Yamanouchi T, Domae K, Kondo K, Dantas Jr JR, Takahashi M, Yamanishi K (1985) Isolation of hemorrhagic fever with renal syndrome virus from leukocyte of rats and virus replication in cultures of rat and human macrophages. J Gen Virol 66: 1271–1278

17. Nakamura T, Yanagihara R, Gibbs JC Jr, Amyx LH, Gajdusek CD (1985) Different susceptibility and resistance of immunocompetent and immunodeficient mice to fatal hantaan virus infection. Arch Virol 86: 109–120

18. Nakamura T, Yanagihara R, Gibbs CJ Jr, Gajdusek CD (1985) Immune spleen cell-mediated protection against fatal hantaan virus infection in infant mice. J Infect Dis 151: 691–697

19. Prabhakar BS, Nathanson N (1981) Acute rabies death mediated by antibody. Nature 290: 590–591

20. Putnak RJ, Schlesinger JJ (1990) Protection of mice against yellow fever virus en-
Antigenic sites on the envelope protein of Hantaan virus

Antigenic sites on the envelope protein of Hantaan virus by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J Gen Virol 71: 1697–1702

21. Schlesinger JJ, Brandriss MW, Putnak JR, Walsh EE (1990) Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody. J Gen Virol 71: 593–599

22. Schlesinger JJ, Brandriss MW, Walsh EE (1987) Protection of mice against Dengue 2 virus encephalitis by immunization with the dengue 2 virus nonstructural glycoprotein NS1. J Gen Virol 68: 853–857

23. Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM (1990) Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants. J Virol 64: 3162–3170

24. Schmaljohn CS, Dalrymple JM (1983) Analysis of Hantaan virus RNA: evidence for a new genus of Bunyaviridae. Virology 131: 482–491

25. Schmaljohn CS, Hasty SE, Harrison SA, Dalrymple JM (1983) Characterization of Hantaan virions, the prototype virus of hemorrhagic fever with renal syndrome. J Infect Dis 148: 1005–1012

26. Schmaljohn AL, Johnson ED, Dalrymple JM, Cole GA (1982) Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature 297: 70–72

27. Song G, Hang CS, Liao HX, Fu JL, Gao GZ, Qiu HL, Zhang QF (1984) Antigenic difference between viral strains causing classical and mild types of epidemic hemorrhagic fever with renal syndrome in China. J Infect Dis 150: 889–894

28. Tamura M, Asada H, Kondo K, Tanishita O, Kurata T, Yamanishi K (1989) Pathogenesis of hantaan virus in mice. J Gen Virol 70: 2897–2906

29. Tan CHc, Yap EH, Singh M, Deubel V, Chan YC (1990) Passive protection studies in mice with monoclonal antibodies directed against the nonstructural protein NS3 of dengue 1 virus. J Gen Virol 71: 745–748

30. Tanishita O, Takahashi Y, Okuno Y, Yamanishi K, Takahashi M (1984) Evaluation of focus reduction neutralization test with peroxidase-antiperoxidase staining technique for hemorrhagic fever with renal syndrome virus. J Clin Microbiol 20: 1213–1215

31. Umino Y, Kohama T, Sato A, Sugiu A (1990) Protective effect of monoclonal antibodies to Newcastle disease virus in passive immunization. J Gen Virol 71: 1199–1203

32. Webb HE, Wight DGD, Platt GS, Smith CEG (1968) Langat virus encephalitis in mice. I. The effect of the administration of specific antiserum. J Hyg 66: 343–354

33. Weiss RC, Scott FW (1981) Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp Immun Microbiol Infect Dis 4: 175–189

34. World Health Organization (1983) Hemorrhagic fever with renal syndrome: memorandum from a WHO meeting. Bull WHO 61: 269–275

35. Yanagihara R, Gajdusek CD (1987) Hemorrhagic fever with renal syndrome: Global epidemiology and ecology of hantavirus infections. Med Virol 6: 198–202

36. Yao JS, Kariwa H, Takashima I, Ariyama J, Hashimoto N (1991) Antibody-dependent enhancement of hantavirus infection in macrophage cell lines. Arch Virol 122: 107–118

37. Zhang XK, Takashima I, Mori F, Hashimoto N (1989) Comparison of virulence between two strains of Rattus serotype hemorrhagic fever with renal syndrome (HFRS) virus in newborn rats. Microbiol Immunol 33: 195–205

Authors' address: Dr. J. Arikawa, Institute of Immunological Science, Hokkaido University, Sapporo 060, Japan.

Received September 10, 1991